Patents Examined by Jared D Barsky
  • Hydroxybupropion and related compounds as modulators of drug plasma levels
    Patent number: 9486450
    Abstract: This disclosure relates to methods administering hydroxybupropion or a prodrug thereof in conjunction with dextromethorphan to a human being. Dosage forms, drug delivery systems, and methods related to dextromethorphan or dextrorphan and hydroxybupropion or a prodrug of hydroxybupropion are also disclosed.
    Type: Grant
    Filed: February 9, 2015
    Date of Patent: November 8, 2016
    Assignee: ANTECIP BIOVENTURES II LLC
    Inventor: Herriot Tabuteau
  • Composition and method for treatment of depression and psychosis in humans
    Patent number: 9486453
    Abstract: Compositions and methods for the treatment of depression and psychoses in humans are disclosed. More particularly, the invention is directed to formulations containing antipsychotic and/or antidepressant medications and also containing an NMDAR antagonist. The present Invention Is also directed to methods tor the treatment of humans suffering from depression and other psychoses, including, schizophrenia, by administration of the inventive compositions in antidepressant and/or antipsychotic effective amounts.
    Type: Grant
    Filed: September 3, 2015
    Date of Patent: November 8, 2016
    Assignee: Glytech LLC
    Inventor: Daniel C. Javitt
  • Sparstolonin B based pharmaceutical agent for neuroblastoma treatment
    Patent number: 9446019
    Abstract: Use of sparstolonin B in inhibition of growth and/or viability of human neuroblastoma cells is described. The sparstolonin B can be naturally derived from the Chinese herb Sparganium stoloniferum or can be synthetic. The sparstolonin B is shown to be effective both in vitro and in vivo in inhibition of growth and/or viability of neuroblastoma cells of multiple different genetic backgrounds including N-myc amplified with wild p53 neuroblastoma cells, N-myc amplified with mutated p53 neuroblastoma cells, and N-myc nonamplified neuroblastoma cells.
    Type: Grant
    Filed: September 11, 2014
    Date of Patent: September 20, 2016
    Assignee: University of South Carolina
    Inventors: Ambrish Kumar, Ugra Sen Singh, Daping Fan, Donald J. Dipette
  • Berberine formulations and uses thereof
    Patent number: 9427432
    Abstract: Pharmaceutical compositions comprising berberine for treatment of skin disorders and methods of use thereof.
    Type: Grant
    Filed: December 19, 2014
    Date of Patent: August 30, 2016
    Assignee: TWi Biotechnology, Inc.
    Inventors: Pao-Li Wang, Way-Yu Lin, Chen-Mao Lin, Po-Yuan Tseng
  • Uses of hypoxia-inducible factor inhibitors
    Patent number: 9427413
    Abstract: The present invention relates to treating a hematologic cancer using a Hypoxia-Inducible Factor (HIF inhibitor). The invention also relates to inducing acute myeloid leukemia remission using the HIF inhibitor. The invention further relates to inhibiting a maintenance or survival function of a cancer stem cell (CSC) using the HIF inhibitor.
    Type: Grant
    Filed: June 25, 2010
    Date of Patent: August 30, 2016
    Assignee: OncoImmune, Inc.
    Inventors: Yang Liu, Yin Wang, Yan Liu, Sami N. Malek, Pan Zheng
  • Injectable fibrin composition for bone augmentation
    Patent number: 9421302
    Abstract: The present invention relates to a biodegradable injectable composition for bone augmentation comprising fibrin, a contrast agent and calcium salt-containing particles, as well as a method for bone augmentation in a patient suffering from a bone disorder comprising injecting said composition into a non-mineralized or hollow portion of said bone.
    Type: Grant
    Filed: April 17, 2007
    Date of Patent: August 23, 2016
    Assignees: Baxter International Inc., Baxter Healthcare S.A.
    Inventors: John J. Barry, Andreas Goessl, Heinz Gulle, Monika Mangold, Melitta Bilban
  • Method for improving therapy for autoimmune diseases such as rheumatoid arthritis
    Patent number: 9421186
    Abstract: In the present invention, a method using a combination of iguratimod or a salt thereof and one or more immunosuppressants is useful as a method for the treatment of autoimmune diseases, and with this method adverse effects are lessened. A pharmaceutical composition containing this combination is useful for the treatment of autoimmune diseases. This method and pharmaceutical composition are useful for the treatment of more severe autoimmune diseases.
    Type: Grant
    Filed: August 29, 2012
    Date of Patent: August 23, 2016
    Assignee: TOYAMA CHEMICAL CO., LTD.
    Inventor: Keiichi Tanaka
  • Heteroaryl compounds and uses thereof
    Patent number: 9415049
    Abstract: The present invention provides compounds, pharmaceutically acceptable compositions thereof, and methods of using the same.
    Type: Grant
    Filed: December 20, 2013
    Date of Patent: August 16, 2016
    Assignee: Celgene Avilomics Research, Inc.
    Inventors: Richland Tester, Prasoon Chaturvedi, Zhendong Zhu, Sekhar S. Surapaneni, Lisa Beebe
  • Methods and pharmaceutical compositions for treatment of cystic fibrosis
    Patent number: 9402821
    Abstract: The present invention relates to a method and compositions for the treatment of cystic fibrosis.
    Type: Grant
    Filed: August 13, 2013
    Date of Patent: August 2, 2016
    Assignees: INSERM (Institut National de la Sante et de la Recherche Medicale), Universite Paris-Est Creteil Val de Marne, Assistance Publique-Hopitaux de Paris
    Inventors: Agathe Tarze, Pascale Fanen
  • Oromucosal liquid estradiol compositions
    Patent number: 9402811
    Abstract: The present invention relates to low dose estradiol solutions for oromucosal administration suitable in replacement therapy or suppletion of low estradiol levels and also for preventing, alleviating or treating symptoms associated with low endogenous levels of estradiol in female subjects.
    Type: Grant
    Filed: January 4, 2013
    Date of Patent: August 2, 2016
    Assignee: INNOTESTO BVBA
    Inventor: Franciscus Wilhelmus Henricus Maria Merkus
  • Compositions and methods of using threohydroxybupropion for therapeutic purposes
    Patent number: 9402843
    Abstract: This disclosure relates to methods administering threohydroxybupropion or a prodrug thereof in conjunction with dextromethorphan to a human being. Dosage forms, drug delivery systems, and methods related to dextromethorphan or dextrorphan and threohydroxybupropion or a prodrug of threohydroxybupropion are also disclosed.
    Type: Grant
    Filed: January 21, 2015
    Date of Patent: August 2, 2016
    Assignee: ANTECIP BIOVENTURES II LLC
    Inventor: Herriot Tabuteau
  • Methods of modulating drug plasma levels using erythrohydroxybupropion
    Patent number: 9402844
    Abstract: This disclosure relates to methods administering erythrohydroxybupropion or a prodrug thereof in conjunction with dextromethorphan to a human being.
    Type: Grant
    Filed: February 20, 2015
    Date of Patent: August 2, 2016
    Assignee: ANTECIP BIOVENTURES II LLC
    Inventor: Herriot Tabuteau
  • Treatment of drug resistant cancer
    Patent number: 9399028
    Abstract: The present invention discloses novel agents and methods for diagnosis and treatment of melanoma. Also disclosed are related arrays, kits, and screening methods.
    Type: Grant
    Filed: September 15, 2014
    Date of Patent: July 26, 2016
    Assignee: The Rockefeller University
    Inventors: Sohail Tavazoie, Nora Pencheva
  • Procaspase 3 activation by combination therapy
    Patent number: 9399035
    Abstract: The invention provides compositions and methods for the induction of cell death, for example, cancer cell death. Combinations of compounds and related methods of use are disclosed, including the use of compounds in therapy for the treatment of cancer and selective induction of apoptosis in cells. The disclosed drug combinations can have lower neurotoxicity effects than other compounds and combinations of compounds.
    Type: Grant
    Filed: March 6, 2013
    Date of Patent: July 26, 2016
    Assignees: The Board of Trustees of the University of Illinois, Vanquish Oncology, Inc.
    Inventors: Paul J. Hergenrother, Rachel C. Botham, Timothy M. Fan, Mark J. Gilbert, Michael K. Handley, Howard S. Roth, Theodore M. Tarasow
  • Functionalized fullerenes as a biomass stimulant and a life extension agent
    Patent number: 9399756
    Abstract: Methods of stimulating an increase in biomass by stimulating the growth, lifespan and/or reproduction of organisms such as fungi, algae, plants, and other aquatic organisms are provided by applying an effective amount of functionalized fullerenes. For example, polyhydroxy fullerenes are effective at low levels of promoting the increase in biomass.
    Type: Grant
    Filed: April 7, 2011
    Date of Patent: July 26, 2016
    Assignee: UNIVERSITY OF FLORIDA RESEARCH FOUNDATION, INC.
    Inventors: Jie Gao, Vijay Krishna, Wei Bai, Benjamin L. Koopman, Brij M. Moudgil, Paul Anthony Indeglia, Kevin Michael Folta, Angelina Tsenova Georgieva
  • Isothiazolopyridinones useful for the treatment of (inter alia) cystic fibrosis
    Patent number: 9399648
    Abstract: The present invention relates to modulators of ATP-Binding Cassette (“ABC”) transporters or fragments thereof, including Cystic Fibrosis Transmembrane Conductance Regulator, compositions thereof, and methods therewith. The present invention also relates to methods of treating ABC transporter mediated diseases using such modulators.
    Type: Grant
    Filed: June 27, 2014
    Date of Patent: July 26, 2016
    Assignee: Vertex Pharmaceuticals Incorporated
    Inventor: Alejandra Gallardo-Godoy
  • Fat composition
    Patent number: 9399041
    Abstract: Provided is a fat or oil composition, comprising the following components (A) and (B): (A) 0.4 to 6 mass % of a free type triterpene alcohol; and (B) 0.2 to 3 mass of a free type phytosterol containing 20 mass % or more of ?-sitosterol, in which a content mass ratio of the free type triterpene alcohol (A) to the free type phytosterol (B), [(A)/(B)], is 0.9 or more.
    Type: Grant
    Filed: October 11, 2012
    Date of Patent: July 26, 2016
    Assignee: KAO CORPORATION
    Inventor: Rika Homma
  • Nitroxide hydroxylamine and phenylenediamine combinations as polymerization inhibitors for ethylenically unsaturated monomer processes
    Patent number: 9399622
    Abstract: Polymerization inhibitor compositions are provided. The polymerization inhibitor compositions may include at least one hydroxylamine of a nitroxide and at least one phenylenediamine. Methods of inhibiting the unwanted polymerization of monomers are also provided. The methods include adding the presently disclosed polymerization inhibitor compositions to a fluid containing the monomers. The monomers may be ethylenically unsaturated monomers, such as acrylic acid, methacrylic acid, acrylonitrile, methacrylonitrile, acrolein, methacrolein, acrylate, methacrylate, acrylamide, methacrylamide, vinyl acetate, butadiene, ethylene, propylene, and styrene.
    Type: Grant
    Filed: December 3, 2013
    Date of Patent: July 26, 2016
    Assignee: ECOLAB USA INC.
    Inventor: David Youdong Tong
  • Compositions and methods for treating severe thrombocytopenia related disease
    Patent number: 9393251
    Abstract: Compositions and methods of treating severe thrombocytopenia and related disease are provided.
    Type: Grant
    Filed: February 19, 2014
    Date of Patent: July 19, 2016
    Inventor: Barry I. Bockow
  • Male contraceptive compositions and methods of use
    Patent number: 9301962
    Abstract: The invention relates to compositions and methods for effecting male contraception.
    Type: Grant
    Filed: May 16, 2011
    Date of Patent: April 5, 2016
    Assignees: Baylor College of Medicine, Dana Farber Cancer Institute, Inc.
    Inventors: James Elliott Bradner, Martin Matzuk, Jun Qi